Needham & Company LLC Reiterates “Buy” Rating for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating restated by research analysts at Needham & Company LLC in a report issued on Thursday,Benzinga reports. They presently have a $56.00 price objective on the specialty pharmaceutical company’s stock, up from their previous price objective of $54.00. Needham & Company LLC’s price target indicates a potential upside of 57.81% from the stock’s previous close.

COLL has been the topic of a number of other reports. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Weiss Ratings cut shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. Barclays decreased their price objective on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research report on Friday, January 9th. Truist Financial set a $58.00 target price on shares of Collegium Pharmaceutical in a research note on Tuesday, February 10th. Finally, Wall Street Zen cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $53.40.

Collegium Pharmaceutical Trading Down 2.2%

NASDAQ COLL opened at $35.49 on Thursday. Collegium Pharmaceutical has a 12-month low of $23.23 and a 12-month high of $50.79. The company has a fifty day simple moving average of $43.26 and a two-hundred day simple moving average of $41.88. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59. The stock has a market cap of $1.13 billion, a P/E ratio of 20.75 and a beta of 0.67.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). The company had revenue of $205.45 million for the quarter, compared to analysts’ expectations of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. Collegium Pharmaceutical’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period last year, the firm earned $1.77 earnings per share. On average, analysts forecast that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP David Dieter sold 13,976 shares of the stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the transaction, the executive vice president directly owned 77,071 shares of the company’s stock, valued at $2,691,319.32. This trade represents a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Scott Dreyer sold 49,976 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the sale, the executive vice president directly owned 71,770 shares of the company’s stock, valued at $2,900,225.70. This represents a 41.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.51% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC raised its holdings in shares of Collegium Pharmaceutical by 59.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock valued at $67,026,000 after acquiring an additional 538,337 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Collegium Pharmaceutical by 65.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock worth $60,776,000 after acquiring an additional 518,721 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Collegium Pharmaceutical by 248.5% in the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after acquiring an additional 461,914 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Collegium Pharmaceutical by 161.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 511,698 shares of the specialty pharmaceutical company’s stock worth $23,692,000 after purchasing an additional 316,109 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in Collegium Pharmaceutical by 897.2% in the 3rd quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock valued at $9,423,000 after purchasing an additional 242,310 shares during the last quarter.

Key Stories Impacting Collegium Pharmaceutical

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Collegium agreed to acquire AZSTARYS from Corium, adding a differentiated ADHD medicine to its portfolio; company says the asset is expected to generate over $50M in pro‑forma net revenue in H2 2026, offers patent protection into 2037, and the deal is expected to be immediately accretive to adjusted EBITDA. Collegium to Acquire AZSTARYS from Corium Therapeutics (GlobeNewswire)
• Positive Sentiment: Sell‑side support strengthened: HC Wainwright reaffirmed a Buy with a $60 PT and Needham reaffirmed Buy with a $56 PT — both imply substantial upside vs. the recent share price, which can underpin investor confidence. Analyst Coverage (Benzinga)
• Neutral Sentiment: Conference call and management discussion transcripts are available for investors seeking details on deal economics and integration plans. Acquisition Discussion Transcript (Seeking Alpha)
• Neutral Sentiment: FDA news elsewhere in the pharma sector: PharmExec reports approval of Wegovy HD (Novo Nordisk) — relevant for sector context but not directly tied to Collegium’s ADHD/pain-focused franchise. FDA Approves Wegovy HD (PharmExec)
• Neutral Sentiment: Public press coverage shows deal price described with varying figures (reports cite up to $785M and also $650M headlines) — read releases for definitive terms. Collegium to buy AZSTARYS for up to $785M (MSN)
• Negative Sentiment: The acquisition costs and financing raise near‑term financial risk: the deal is being funded from cash on hand plus a previously announced $300M delayed‑draw term loan, which increases leverage for a company that already shows a relatively high debt/equity ratio; investors may worry about cash burn, integration execution and balance‑sheet pressure. Deal Coverage (FiercePharma)
• Negative Sentiment: Recent quarterly results (Feb. 26) showed a slight revenue and EPS miss vs. consensus, which combined with the large acquisition outlay can pressure near‑term sentiment as investors await proof the deal accelerates growth. Earnings Summary (Benzinga)
• Neutral Sentiment: Reported short‑interest data appears anomalous (shows zero shares), so it does not provide a meaningful read into market positioning at this time.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.